Document is current

Article History

Received: 12 July 2024

Accepted: 23 October 2025

First Online: 29 December 2025

Declarations

:

: This study received ethical approval from the Comité de Protection des Personnes Sud-Est VI on March 3, 2024 (N° ID-RCB: 2023-A02762-43; Ref AU 1925). Although no patients were involved in the study design, it warrants noting that three members of the local ethics committee that approved the study were user representatives. All eligible patients will be proposed to participate by nurses or medical oncologists, who will give them an information file. All patients will give their written informed consent before any study procedure. The study will be conducted in accordance with European Regulation (EU) 2017/745 on medical devices, the law related to the protection of physical persons for the treatments of personal data and related to information technology, database and liberties, the Helsinki declaration, and Good Clinical Practices (GCP) for Medical Devices (ISO 14155).

: Not applicable.

: AF declares advisory/consultancy fees (personal) for Cureety. FM declares advisory/consultancy roles (from eXYSTAT) for Cureety and owns shares of Cureety. CP and FGC are employees and own shares of Cureety. JB, FG, RR, JMG, AE, LG, BC declare research grant/funding (institution) from Cureety. TS declares no competing interest.